Understanding Participation Habits Among Plaque Psoriasis Patients
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Power Life Sciences Inc.
- Study ID
- NCT06338358
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The study intends to investigate the personal experiences of plaque psoriasis patients who take part in a separate clinical study including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal. The data collected from this study will help improve future outcomes for all plaque psoriasis as well as those in under-represented demographic groups.
Key Dates
- Start date
- Apr 30, 2025
- Status verified
- Mar 2024
- Primary completion
- Apr 30, 2026
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 500 participants (estimated)
Primary Outcome Measure
Rate of patients who decide to enroll in a plaque psoriasis clinical research. [ Time Frame: 3 months ]
Central Contacts
- Michael B Gill(415) 900-4227
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Power Life Sciences | San Francisco | California | 94107 |
Find similar trials in San Francisco, CA
Related Studies
- A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque PsoriasisPHASE3 · Recruiting · Bristol-Myers Squibb · Birmingham, Alabama
- Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)PHASE3 · Recruiting · Bristol-Myers Squibb · Birmingham, Alabama
- A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque PsoriasisPHASE3 · Recruiting · Takeda · Chula Vista, California
- Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque PsoriasisPHASE2 · Recruiting · Oruka Therapeutics, Inc. · Phoenix, Arizona